Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-06T07:20:14.314Z Has data issue: false hasContentIssue false

100 - Prophylaxis of Opportunistic Infections in HIV Infection

from Part XII - HIV

Published online by Cambridge University Press:  05 March 2013

Judith A. Aberg
Affiliation:
New York University School of Medicine
David Schlossberg
Affiliation:
Temple University School of Medicine, Philadelphia
Get access

Summary

The use of infection prophylaxis has been a major advance in human immunodeficiency virus (HIV) disease. Even prior to the introduction of potent antiretroviral therapies, the morbidity and mortality rates were decreasing presumably due to recognition of pathogens and use of prophylaxis for opportunistic infections. The Centers for Disease Control and Prevention (CDC) published the 2002 update of the United States Public Health Service/Infectious Diseases Society of America guidelines for opportunistic infection prophylaxis in HIV disease. The major update pertains to the data generated since the 1999 edition regarding the safety of discontinuing both primary and secondary prophylaxis for several opportunistic infections. There are some minor differences with regard to duration of time the CD4 count increases above a set threshold before stopping prophylaxis and the duration of treatment for pathogen-specific diseases, most of which can be attributed to the study designs of the prophylaxis discontinuation trials for that specific pathogen.

Primary prophylaxis is that given before development of an infection. The best known and most effective is trimethoprim–sulfamethoxazole (TMP-SMX) prophylaxis against Pneumocystis jiroveci pneumonia, formerly known as Pneumocytis carinii (PCP). TMP-SMX is 90% or more effective and is estimated to add a year to survival in late HIV disease. Other prophylaxes that are highly effective (≥70% efficacy) have now become standard of care in HIV disease: prophylaxis against tuberculosis (TB) if there has been exposure or a positive tuberculin skin test and against disseminated Mycobacterium avium complex (MAC) infection and toxoplasmosis.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×